



Fabhalta in Qatar

The MOPH named-patient coordination pathway — indicative 2026

RARE DISEASE · PNH / IGA NEPHROPATHY

The clinical situation

Fabhalta (iptacopan) is an FDA-approved oral complement factor B inhibitor indicated for paroxysmal nocturnal hemoglobinuria (PNH) and primary IgA nephropathy at risk of progression. Manufactured by Novartis. Dosed 200 mg orally twice daily; meningococcal, pneumococcal, and H. influenzae vaccination required before initiation. Stored at controlled room temperature.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating hematologist or nephrologist confirms diagnosis and documents the clinical rationale; required vaccinations are administered.
- 2 Monitoring plan confirmed.** A Qatari tertiary hospital or specialty clinic accepts the case for ongoing laboratory monitoring.
- 3 MOPH named-patient application.** Clinical rationale, patient reference, product details, and supply plan filed with the Qatar Ministry of Public Health.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Arrival & dispensing.** The clinic receives the supply; twice-daily oral dosing under physician monitoring, refill cycles coordinated on a rolling basis.

Indicative economics

Reference US cash-pay range: USD 55,000–65,000 per 30-day supply. Logistics, MOPH documentation, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete MOPH application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MOPH review. **Logistics.** Temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Fabhalta × Qatar first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/fabhalta-qatar.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team